Pharmacokinetics of TAF When Used With Other Antiretrovirals Pharmacokinetics of TAF When Used With Other Antiretrovirals
How might other antiretroviral agents for the treatment of HIV impact the pharmacokinetics of tenofovir alafenamide?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 16, 2018 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

In Utero Tenofovir Exposure May Not Affect Infant Bones In Utero Tenofovir Exposure May Not Affect Infant Bones
A new pilot study suggests prenatal tenofovir exposure does not have a significant effect on infant bone mineral content (BMC) or bone mineral density (BMD).Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 14, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Transgender Hormonal Therapy Might Interfere with PrEP
(MedPage Today) -- 13% decrease in tenofovir availability; unclear whether it compromises protection (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - July 26, 2018 Category: Endocrinology Source Type: news

Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir   Alafenamide Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 25, 2018 Category: Drugs & Pharmacology Source Type: news

Access to Treatment for Hepatitis B Virus Infection - Worldwide, 2016
Among persons living with HBV worldwide, approximately 27 million (10.5%) were aware of their infection, including 4.5 million (16.7%) who were on treatment. In 2017, all but two low- and middle-income countries could legally procure generic entecavir or tenofovir, the medicines active against HBV infection. (Source: PHPartners.org)
Source: PHPartners.org - July 19, 2018 Category: International Medicine & Public Health Source Type: news

Zoledronic Acid Superior to ART-switching for Low Bone Density in HIV Zoledronic Acid Superior to ART-switching for Low Bone Density in HIV
Zoledronic acid improves low bone mineral density (BMD) better than switching from tenofovir disoproxil fumarate (TDF) to another antiretroviral drug in adults with HIV, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA Approves Symtuza (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
TITUSVILLE, N.J, JULY 17, 2018 – The Janssen Pharmaceutical Companies of Johnson& Johnson today announced the U.S. Food and Drug Administration (FDA) has approved Symtuza (darunavir, cobicistat, emtricitabine and tenofovir alafenamide -... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 17, 2018 Category: Drugs & Pharmacology Source Type: news

Fixed-Dose Bictegravir-Emtricitabine-Tenofovir Maintains Virologic Suppression in HIV Fixed-Dose Bictegravir-Emtricitabine-Tenofovir Maintains Virologic Suppression in HIV
Fixed-dose bictegravir-emtricitabine-tenofovir (Biktarvy) maintains virologic suppression in adults with HIV-1 who are switched from dolutegravir-abacavir-lamivudine or from boosted protease inhibitor-based regimens, according to results from two noninferiority trials.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 13, 2018 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

FDA Approves Expanded Indication for Truvada (emtricitabine and tenofovir disoproxil fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 15, 2018-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 15, 2018 Category: Drugs & Pharmacology Source Type: news

ART With Tenofovir Backbone Not Linked to Worse Outcomes ART With Tenofovir Backbone Not Linked to Worse Outcomes
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 2, 2018 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

EMA Panel Recommends Once-Daily HIV-1 Treatment Biktarvy EMA Panel Recommends Once-Daily HIV-1 Treatment Biktarvy
EMA panel recommends marketing authorization for a once-daily HIV-1 combo containing bictegravir, emtricitabine, and tenofovir.International Approvals (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 27, 2018 Category: Internal Medicine Tags: HIV/AIDS News Alert Source Type: news

No Higher Risk for Adverse Birth Outcomes with 3-Drug HIV Tx (CME/CE)
(MedPage Today) -- Tenofovir, emtricitabine, and ritonavir-boosted lopinavir compared with other ART (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - April 25, 2018 Category: OBGYN Source Type: news

Risk of Adverse Birth Outcomes No Higher With TDF-FTC-LPV/r
WEDNESDAY, April 25, 2018 -- For HIV-infected women and their infants, the risk of adverse birth outcomes is similar with tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) compared with zidovudine, lamivudine, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 25, 2018 Category: Pharmaceuticals Source Type: news

HIV Drug, Tenofovir, Appears Safe During Pregnancy
WEDNESDAY, April 25, 2018 -- Drugs to prevent HIV-positive pregnant women from infecting their unborn babies appear safe and don't raise the risk for premature birth or infant death, new research indicates. The U.S. scientists said their findings... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 25, 2018 Category: General Medicine Source Type: news

SYMFI (efavirenz, lamivudine and tenofovir disoproxil fumarate) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 5, 2018 Category: Drugs & Pharmacology Source Type: news

Mylan Introduces Symfi(TM) Triple Combo Once-Daily HIV Treatment in the U.S.
Approval complements growing portfolio of cost-saving antiretroviral medications available to patients in the U.S., including recently announced Symfi Lo™ and Cimduo™ All ARV regimens are being offered at a significant discount to the price of competing... Biopharmaceuticals, HIV/AIDS, FDA, Product Launch Mylan, Symfi, efavirenz, lamivudine, tenofovir (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2018 Category: Pharmaceuticals Source Type: news

Mylan Introduces Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Triple Combo Once-Daily HIV Treatment in the U.S.
HERTFORDSHIRE, England and PITTSBURGH, March 28, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will introduce in the U.S. a third cost-saving HIV combination. The U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 28, 2018 Category: Drugs & Pharmacology Source Type: news

Symfi Lo (Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 22, 2018 Category: Drugs & Pharmacology Source Type: news

Cimduo (Lamivudine and Tenofovir Disoproxil Fumarate Tablets, for Oral Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 21, 2018 Category: Drugs & Pharmacology Source Type: news

Tenofovir Alafenamide Plus Emtricitabine Effective, Safe in HIV Tenofovir Alafenamide Plus Emtricitabine Effective, Safe in HIV
In HIV patients, combination therapy with tenofovir alafenamide and emtricitabine is non-inferior to that of abacavir plus lamivudine, according to a manufacturer-sponsored trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 13, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Tenofovir Fails to Add Extra Hepatitis B Protection for Vaccinated Newborns Tenofovir Fails to Add Extra Hepatitis B Protection for Vaccinated Newborns
Adding tenofovir disoproxil fumarate (TDF) to an aggressive treatment strategy fails to give extra protection to newborns at risk for contracting hepatitis B virus (HBV) from their infected mothers, according to a study at 17 public hospitals in Thailand.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 8, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Antiviral drug not beneficial for reducing mother-to-child transmission of hepatitis B when added to existing preventatives, study shows
(NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development) Tenofovir disoproxil fumarate (TDF), an antiviral drug commonly prescribed to treat hepatitis B infection, does not significantly reduce mother-to-child transmission of hepatitis B virus when taken during pregnancy and after delivery, according to a phase III clinical trial in Thailand funded by the National Institutes of Health. The study tested TDF therapy in addition to the standard preventative regimen -- administration of hepatitis B vaccine and protective antibodies at birth -- to explore the drug's potential effects on mother-to-ch...
Source: EurekAlert! - Infectious and Emerging Diseases - March 7, 2018 Category: Infectious Diseases Source Type: news

Tenofovir Gel Less Effective in Women With Genital Inflammation Tenofovir Gel Less Effective in Women With Genital Inflammation
Tenofovir gel is less effective in preventing HIV in women with genital inflammation, according to a post hoc analysis of data from the CAPRISA 004 study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 6, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Mylan to Introduce Cimduo (lamivudine and tenofovir disoproxil fumarate) as a New Cost-Saving HIV Combination Treatment in the U.S.
HERTFORDSHIRE, England and PITTSBURGH, March 2, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will launch Cimduo, which was approved in February by the U.S. Food and Drug Administration (FDA).... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 2, 2018 Category: Drugs & Pharmacology Source Type: news

Mylan to Introduce Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) as a New Cost-Saving HIV Combination Treatment in the U.S.
HERTFORDSHIRE, England and PITTSBURGH, March 2, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will launch a new HIV treatment, Symfi Lo, which was approved in February by the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 2, 2018 Category: Drugs & Pharmacology Source Type: news

Mylan to Introduce Two New Cost-Saving HIV Combination Treatments in the U.S.
FDA recently approved Symfi Lo™, a three-drug single-tablet antiretroviral (ARV) regimen, and Cimduo™, a double combination, for HIV treatment Mylan will launch Symfi Lo and Cimduo at a significant discount to the price of competing products to bring co... Biopharmaceuticals, HIV/AIDS, Product Launch Mylan, Symfi Lo, Cimduo, efavirenz, lamivudine, tenofovir (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 2, 2018 Category: Pharmaceuticals Source Type: news

Monthly News Roundup - February 2018
Gilead ’s Biktarvy Cleared for Use in HIV-1 Infection In February, the FDA approved Gilead's Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide, or BIC/FTC/TAF), a combination, once-daily, oral treatment for HIV-1 infection in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 28, 2018 Category: Pharmaceuticals Source Type: news

Genital inflammation reduces efficacy of tenofovir gel
(Columbia University's Mailman School of Public Health) A new study shows that genital inflammation significantly reduces the effectiveness of tenofovir gel in preventing HIV infection in women. These findings indicate that both genital inflammation and adherence need to be addressed to improve the effectiveness of topical pre-exposure prophylaxis strategies for HIV prevention in women. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 28, 2018 Category: Infectious Diseases Source Type: news

Pharmacokinetics of Tenofovir Vaginal Gel Differs by Age Pharmacokinetics of Tenofovir Vaginal Gel Differs by Age
The pharmacokinetics of tenofovir vaginal gel differs between premenopausal and postmenopausal women, likely because of differences in the state of the cervicovaginal mucosa, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 20, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Biktarvy (Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 14, 2018 Category: Drugs & Pharmacology Source Type: news

New 3-Drug Combo for HIV OK'd
(MedPage Today) -- Gilead's Biktarvy includes bictegravir, emtricitabine, and tenofovir alafenamide (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 8, 2018 Category: Primary Care Source Type: news

FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 7, 2018 Category: Drugs & Pharmacology Source Type: news

Cipla gets USFDA approval for HIV drug
Citing IMS Health data, the company said Viread Tablets, 300mg, had US sales of approximately USD 725 million for the 12-month period ending November 2017. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 29, 2018 Category: Pharmaceuticals Source Type: news

HIV Prevention Trials Network (HPTN) announces initiation of HPTN 084
(FHI360) The HIV Prevention Trials Network (HPTN) today announced the initiation of HPTN 084, a Phase 3 double-blind safety and efficacy study of long-acting injectable cabotegravir (CAB) compared to a combination of daily oral tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg (TDF/FTC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 30, 2017 Category: International Medicine & Public Health Source Type: news

Single-Pill HIV Regimen Scores in New Patients Single-Pill HIV Regimen Scores in New Patients
A new single-tablet regimen with boosted darunavir and tenofovir alafenamide works in virally suppressed HIV patients, AMBER trial results confirm, but when should it be tried in the treatment na ï ve?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 3, 2017 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

Tenofovir Prodrug Goes Head to Head Against Abacavir in HIV Tenofovir Prodrug Goes Head to Head Against Abacavir in HIV
A lot has been made of the better renal and bone safety with the tenofovir alafenamide prodrug than with the older formulation, but is it better than other antiretrovirals?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 1, 2017 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

Single-tablet Switch Option Effective in Virologically Suppressed HIV Single-tablet Switch Option Effective in Virologically Suppressed HIV
A new single-tablet regimen (STR) that includes the protease inhibitor (PI) darunavir, cobicistat, emtricitabine, and tenofovir alafenamide maintains viral suppression in adults infected with HIV-1, according to results from the EMERALD phase 3 noninferiority trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 20, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1
Janssen seeks approval for investigational regimen that aims to combine efficacy, durability, and the high genetic barrier to resistance of darunavir with the renal and bone safety profile of emtricitabine/tenofovir alafenamide in a once daily pill (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 19, 2017 Category: Pharmaceuticals Source Type: news

HIV prevention drug could save NHS £1 billion over 80 years
Conclusion Evidence to support the use of Prep is building. Studies have shown that it is very effective at reducing the chances of becoming infected with HIV, for men at risk of infection through unprotected sex with men. The question is more about the cost of treatment – and who should fund it – than whether it works. NHS England previously went to court to say that it should not be responsible for funding Prep, as it is a preventive treatment, and therefore should come under health promotion budgets held by local authorities. The High Court ruled that the NHS was able to fund the drug. NHS England has since ...
Source: NHS News Feed - October 19, 2017 Category: Consumer Health News Tags: Medication Source Type: news

Janssen Announces Pivotal Phase 3 Study Results for Investigational Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection in Adults Switching from Boosted Protease Inhibitors Plus Emtricitabine and Tenofovir Disoproxil Fumarate Regimens
EMERALD 48-week safety and efficacy results published in The Lancet HIV and to be presented at IDWeek (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 6, 2017 Category: Pharmaceuticals Source Type: news

Higher-Dose, Once-Daily Raltegravir Regimen for HIV-1 Higher-Dose, Once-Daily Raltegravir Regimen for HIV-1
A 1,200-mg, once-daily regimen of raltegravir, in combination with tenofovir disoproxil fumarate and emtricitabine, is effective in patients with previously untreated HIV-1 infection, according to results from the ONCEMRK trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 26, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

New Guidelines Issued on HIV Treatment During Pregnancy (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Tenofovir-emtricitabine should not be a first treatment choice for women with HIV who are pregnant, according to new patient-centered … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 12, 2017 Category: Primary Care Source Type: news

Maraviroc-containing Regimens Appear Safe for HIV PrEP in Women Maraviroc-containing Regimens Appear Safe for HIV PrEP in Women
Maraviroc-containing regimens appear to be safe and well tolerated, compared with tenofovir-emtricitabine (TDF-FTC), for preventing HIV infection in women, according to results from a phase 2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 22, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Aurobindo Pharma gets USFDA nod for anti-HIV drug
Aurobindo Pharma has received tentative approval from the USFDA for dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, used for the treatment of HIV, in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 21, 2017 Category: Pharmaceuticals Source Type: news

Mylan rolls out HIV treatment medicine in Canada
Mylan launched three generic medications to treat HIV in Canada. The pharmaceutical company, which is based in the Netherlands but run out of its corporate offices in Canonsburg, said it had received Health Canada approval for these generic drugs: emtricitabine/tenofovir disoproxil fumarate 200 mg/300 mg, a generic alternative to Truvada efavirenz/emtricitabin e/tenofovir disoproxil fumarate 600 mg, 200 mg, and 300 mg, a generic alternative to Atripla tenofovir disoproxil 300 mg, a generic alternative… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 10, 2017 Category: American Health Authors: Paul J. Gough Source Type: news

Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada
Mylan now offers generic alternatives to Truvada®, Atripla® and Viread® to patients in Canada1 HERTFORDSHIRE, England and PITTSBURGH and TORONTO, Aug. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan Pharmaceuticals ULC, a subsid... Biopharmaceuticals, Generics, Product Launch Mylan, Truvada, Atripla, Viread (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 10, 2017 Category: Pharmaceuticals Source Type: news

Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 10, 2017-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company ’s New Drug Application (NDA) for an... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - August 10, 2017 Category: Drugs & Pharmacology Source Type: news

Mylan launches new HIV treatment in India
Mylan NV said it is the first company to offer an innovative, reduced-dose HIV treatment in India. Mylan (Nasdaq:MYL) subsidiary Mylan Pharmaceuticals Private Limited has received marketing authorization from the Drug Controller General of India for its antiretroviral drug Avonza. The fixed-dose combination comprised of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets is recommen ded by the World Health Organization as an alternative first-line regimen for people being treated for… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 9, 2017 Category: Pharmaceuticals Authors: Patty Tascarella Source Type: news

Lower Risk of Adverse Birth Outcomes With Tenofovir-emtricitabine-efavirenz Lower Risk of Adverse Birth Outcomes With Tenofovir-emtricitabine-efavirenz
Exposure of infants, from conception, to the antiretroviral combination of tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TFC-FTC-EFV) is associated with a lower risk of adverse birth outcomes, compared with exposure to other antiretroviral regimens, according to data from Botswana.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Bone Risk with Tenofovir: How to Handle? (CME/CE)
(MedPage Today) -- Studies examine role of common HIV drug (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 28, 2017 Category: Primary Care Source Type: news